LEN vs SPRB · rev $34.19B vs rev $4.9M
LEN (LEN) versus Spruce Biosciences Inc (SPRB) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
Spruce Biosciences Inc (SPRB) is a biotechnology company listed on US.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
Latest reported SPRB revenue for 2024-12-31 was $4.9M. Net income was -$53.0M. Revenue was down 51.3% from 2023-12-31 to 2024-12-31. SPRB currently screens at market cap $3.0M.
LEN currently screens at market cap $0. SPRB currently screens at market cap $3.0M.
Not investment advice. Open the LEN and SPRB stock pages for the full models.
Not investment advice.